Company intelligence / Profile preview

NeoChord

Maple Grove, Minnesota, United Statesneochord.com ↗

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

NeoChord’s DS1000 transapical artificial chordae delivery system is commercially available in Europe and has been used to place over 5,000 neochordae in more than 2,000 patients. The NeXus transseptal system is currently undergoing feasibility clinical trials. Clinical results indicate that these minimally invasive procedures can restore normal mitral valve function with reduced invasiveness compared to traditional surgery.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

2 assets

NeoChord DS1000

Commercial

Indications: Mitral valve regurgitation

1 more asset in the full pipeline.

Request access →

Partnerships

Mayo Clinic (exclusive worldwide license for initial technology development and commercialization)

Beyond the preview

Go deeper on NeoChord.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoChord.

Explore the full profile